.

Akuku Danger Explains Personal Decision To Remain Childless

Comedian Mannerson Ochieng, popularly known as Akuku Danger, has shared the deeply personal and difficult decision he has made to remain childless, citing his lifelong battle with sickle cell anemia.

Speaking in an interview with a local TV station on Wednesday, October 1, 2025, the comedian explained that while he is physically able to father children, he has deliberately chosen not to out of fear of passing the debilitating genetic condition to the next generation.

“As a person, mimi saa hizi bado sina mtoto. It is not that I can’t; I can. But I choose to live a life yenye I have to be very keen on what happens around me,” Akuku Danger stated.

“I wouldn’t want to bring another child in this world mwenye bado anaenda kuwa na the same condition.”

Prioritizing Health Over Procreation

Akuku Danger’s revelation comes amidst studies highlighting the severe impact of sickle cell anemia, a condition linked to high levels of childhood mortality in Kenya.

He revealed that he has taken proactive measures, including medical screenings, to understand the genetic risks. He noted that if he were ever to consider starting a family, he would only proceed after ensuring that his partner is not a carrier of the sickle cell gene.

However, he emphasized that even with a healthy partner, he has already made a firm, personal choice to have a childless marriage to ensure the condition dies with him. “It is my job to make sure that sickle cell dies with me,” he asserted, concluding:

“Tumeenda screening, but as a person, I have actually decided to have a marriage that is childless. Sitaki mtoto mimi.”

Akuku Danger’s heartfelt transparency sheds light on the profound ethical and emotional choices faced by those living with genetic illnesses. The comedian continues to use his platform to both entertain and raise vital awareness about sickle cell anemia, affecting countless families across Kenya and East Africa.

About this writer:

Dennis Elnino

Content Developer Email: [email protected]